SciClone's shares dip as pancreatic cancer trial stopped
This article was originally published in Scrip
SciClone Pharmaceuticals' shares took a knock earlier this week following the discontinuation of a Phase II trial evaluating RP101 (also known as BVdU), for the treatment of late-stage pancreatic cancer in response to a recommendation from the data safety monitoring committee.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.